Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase

Prostate

Volumn 67, Issue 10, 2007, Pages 1019-1028

  Klyushnenkova, Elena N ^a,b   Kouiavskaia, Diana V ^a   Kodak, James A ^a   Vandenbark, Arthur A ^c,d   Alexander, Richard B ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CD4 T lymphocytes; DR2 transgenic mice; HLA DR15; Prostate cancer; Prostatitis

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; PEPTIDE; T LYMPHOCYTE ANTIGEN;

ALLELE; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CHRONIC PROSTATITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; HLA SYSTEM; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; EPITOPES; HLA-DR ANTIGENS; HLA-DR2 ANTIGEN; HUMANS; MALE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDES; PROSTATIC NEOPLASMS; PROSTATITIS; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 34250831523     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20575     Document Type: Article

References (49)

1. Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology. Curr Probl Cancer 1991;15:299-360.
2. Harada M, Noguchi M, Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol 2003;8:193-199.
3. McNeel DG, Knutson KL, Schiffman K, Davis DR, Caron D, Disis ML. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 2003;23:62-72.
4. Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res 2005;11:7470-7479.
5. Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P, Mahmud D, Nunez R, Sosman JA, Peace DJ. Induction of specific T-cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 2006;55:1033-1042.
6. Fuessel S, Meye A, Schmitz M, Zastrow S, Linne C, Richter K, Lobel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial. Prostate 2006;66:811-821.
7. Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Yamana H, Noda S. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci 2004;95:77-84.
8. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
9. Singh H, Raghava GP. ProPred: Prediction of HLA-DR binding sites. Bioinformatics 2001;17:1236-1237.
10. Rothbard JB, Taylor WR. A sequence pattern common to T-cell epitopes. EMBO J 1988;7:93-100.
11. Williams MA, Holmes BJ, Sun JC, Bevan MJ. Developing and maintaining protective CD8+ memory T-cells. Immunol Rev 2006;211:146-153.
12. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT. Cognate CD4(+) T-cell licensing of dendritic cells in CD8(+) T-cell immunity. Nat Immunol 2004;5:1143-1148.
13. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T-cells against the autologous tumor. J Immunol 2000;164:3902-3912.
14. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T-cell control of CD8+ T-cell reactivity to a model tumor antigen. J Immunol 2000;164:562-565.
15. Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'day SJ. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006;126:2658-2663.
16. Rosenberg SA, White DE. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;19:81-84.
17. Gregersen JW, Holmes S, Fugger L. Humanized animal models for autoimmune diseases. Tissue Antigens 2004;63:383-394.
18. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A 1999;96:2982-2987.
19. Stillwell TJ, Engen DE, Farrow GM. The clinical spectrum of granulomatous prostatitis: A report of 200 cases. J Urol 1987;138:320-323.
20. Alexander RB, Mann DL, Borkowski AA, Fernandez-Vina M, Klyushnenkova EN, Kodak J, Propert KJ, Kincaid M. Granulomatous prostatitis linked to HLA-DRB1*1501. J Urol 2004;171:2326-2329.
21. Holmes S, Siebold C, Jones EY, Friese MA, Fugger L, Bell J. Multiple sclerosis: MHC associations and therapeutic implications. Expert Rev Mol Med 2005;7:1-17.
22. Klyushnenkova EN, Ponniah S, Rodriguez A, Kodak J, Mann DL, Langerman A, Nishimura MI, Alexander RB. CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J Immunother 2004;27:136-146.
23. Klyushnenkova EN, Link J, Oberle WT, Kodak J, Rich C, Vandenbark AA, Alexander RB. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen. Clin Cancer Res 2005;11:2853-2861.
24. Woods A, Chen HY, Trumbauer ME, Sirotina A, Cummings R, Zaller DM. Human major histocompatibility complex class II-restricted T-cell responses in transgenic mice. J Exp Med 1994;180:173-181.
25. Vandenbark AA, Rich C, Mooney J, Zamora A, Wang C, Huan J, Fugger L, Offner H, Jones R, Burrows GG. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J Immunol 2003;171:127-133.
26. Rich C, Link JM, Zamora A, Jacobsen H, Meza-Romero R, Offner H, Jones R, Burrows GG, Fugger L, Vandenbark AA. Myelin oligodendrocyte glycoprotein- 35-55peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol 2004;34:1251-1261.
27. Kovats S, Drover S, Marshall WH, Freed D, Whiteley PE, Nepom GT, Blum JS. Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome. J Exp Med 1994;179:2017-2022.
28. Inoue Y, Takaue Y, Takei M, Kato K, Kanai S, Harada Y, Tobisu K, Noguchi M, Kakizoe T, Itoh K, Wakasugi H. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. J Urol 2001;166:1508-1513.
29. Machlenkin A, Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother 2007;56:217-226.
30. Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K, Harada M. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 2005;11:6933-6943.
31. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998;36:129-138.
32. Vidovic D, Graddis TJ, Stepan LP, Zaller DM, Laus R. Specific stimulation of MHC-transgenic mouse T-cell hybridomas with xenogeneic APC. Hum Immunol 2003;64:238-244.
33. McNeel DG, Nguyen LD, Disis ML. Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 2001;61:5161-5167.
34. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer. J Immunol 1997;159:3113-3117.
35. Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 2006;24:293-303.
36. Johnson LE, Frye TP, McNeel DG. Immunization of Lewis rats with a prostate cancer xenoantigen elicits predominantly xenoantigen epitope-specific T-cell responses. Proc Am Assoc Cancer Res 2006;47:1174 (Abstract).
37. Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunol Lett 2005;99:85-93.
38. Alexander RB, Brady F, Ponniah S. Autoimmune prostatitis: Evidence of T-cell reactivity with normal prostatic proteins. Urology 1997;50:893-899.
39. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12:29-38.
40. Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000;44:49-54.
41. Motrich RD, Maccioni M, Molina R, Tissera A, Olmedo J, Riera CM, Rivero VE. Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol 2005;116:149-157.
42. Wekerle H, Linington C. Organ specific autoantigens and the autoreactiveT-cell repertoire: The case of myelin oligodendrocyte glycoprotein. Eur J Immunol 2006;36:512-515.
43. Shevach EM. From vanilla to 28 flavors: Multiple varieties of T regulatory cells. Immunity 2006;25:195-201.
44. Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Urol Rep 2006;7:239-246.
45. Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 2006;24:434-441.
46. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001;167:7150-7156.
47. Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. Oncol Rep 2004;12:601-607.
48. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Bohme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006;55:1524-1533.
49. Kramer G, Mitteregger D, Marberger M. Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease? Eur Urol 2007;51:1202-1216.